All posts by: Silvia Salvadori

About Silvia Salvadori

Recently, the Supreme Court once again refused to take up cases involved in the 101 statute (patentable subject matter).  Many briefs were filed by the industry, academics, and the government to urge the Supreme Court to update and clarify what is patentable and what is not patentable. The refusal to intervene may be a signal […]

A few weeks ago (mid-October 2019), the USPTO released an updated (view here) patent subject matter eligibility guidance (PEG) along with new examples related to personalized medicine, therapeutic methods, and pharmaceutical products.   The October update is essentially a clarification of the January 2019 guidance. This update analyzes five areas of the 35 U.S.C. §101 analysis […]

Provisional applications are generally used to provide a valid priority date for an invention claimed in a subsequent non-provisional application. However, even a well drafted provisional application may fail to describe the claimed invention with “adequate specificity.” In a recent case, Purdue Pharma L.P. v. Iancu, the main claim was directed to a controlled release […]